A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

NCT04595162 | Not Yet Recruiting Phase 1

• 1 other identifier: PGC0005
• Study Type: interventional
• Target: 12
• Locations: 0 countries
• Sites: N/A

Brief Summary

The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC019F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 6-12 subjects to receive GC019F therapy.

Conditions

B-cell Acute Lymphoblastic Leukemia

Outcome Measures

Primary Outcomes (1)

• Incidence and severity of adverse events(AE)

  AEs will be collected and graded according to ASTCT consensus(for Cytokine Release Syndrome, CRS and Immune Effector Cell-Associated Neurotoxicity Syndrome, ICANS) and CTCAE v5.0(for AE except for CRS/ICANS )

  15 years

Secondary Outcomes (4)

• CAR copies and concentration of GC007F in peripheral blood, bone marrow and CSF

  2 years

• Overall response rate (ORR) and minimal residual disease negative (MRD-) rate of patients who received GC007F infusion

  2 years

• Duration of response (DOR), progression-free survival (PFS), overall survival (OS) of patients who received GC007F infusion

  15 years

• Concentration of anti-GC007F antibody after infusion

  2 years

Study Arms (1)

CAR-T treatment group

EXPERIMENTAL

The patients will receive one dose of GC019F.

Biological: GC019F

Interventions

GC019F BIOLOGICAL

GC019F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive one single infusion of GC019F.

CAR-T treatment group

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 18-70 years;
• Eastern cooperative oncology group (ECOG) performance status of 0 to 2;
• Life expectancy≥12 weeks;
• CD19 tumor expression demonstrated in bone marrow or peripheral blood by flow cytometry;
• Relapsed or refractory B- ALL: a) Refractory B- ALL: Fail to achieve a CR after 2 cycles of a standard induction chemotherapy regimen or one-line/multi-line salvage chemotherapy; b) Relapsed B- ALL: Relapse after remission for the first time in 12 months or relapse after one-line/multi-line salvage chemotherapy; Relapse is defined as recurrence of primitive cell in peripheral blood or bone marrow(\>5%) after remission; c)Relapse after autologous stem cell transplantation or allogeneic hematopoietic stem cell transplantation; d)Patients with Philadelphia chromosome positive(Ph+) ALL were eligible if they were intolerant to or had failed two lines of tyrosine kinase inhibitor (TKI) therapy, or had t315i mutation.
• Did not receive hematopoietic stem cell transplantation≤6 months prior to enrollment;
• Adequate organ function defined as: a) Creatinine clearance (as estimated by Cockcroft Gault method) \>60 mL/min; b) Serum ALT/AST \<2.5 ULN; c) Total bilirubin \<1.5 ULN (subjects with Gilbert's syndrome≤3 ULN); d) Cardiac ejection fraction≥50%, no evidence of clinically significant pericardial effusion as determined by an ECHO; e) No clinically significant pleural effusion; f) Baseline oxygen saturation \>92% on room air;
• Females of reproductive age must be in non-lactation period. Females of childbearing potential must have a negative serum or urine pregnancy test. All subjects must use medical-approved-contraception (such as intrauterine device and contraceptive drugs) during the treatment and in 2 years after cell transfusion treatment; Males should avoid sperm donation;
• Venous access can be established, peripheral blood mononuclear cells (PBMC) can be collected in researcher's judgement;
• The subject agrees to and sign informed consent form;
• The subject can communicate well with the researcher, is willing and able to comply with the research plans, and finish the research according to the research rule.

You may not qualify if:

• Isolated extramedullary leukemia or isolated extramedullary disease relapse;
• Central nervous system leukemia involved CNS3;
• Concomitant malignancy other than cured non-melanoma skin cancer or cervical carcinoma in situ or localized prostate cancer or superficial bladder cancer or ductal carcinoma in situ or diagnosis of other malignancy exceeds 5 years without relapse or treatment during the 5 years;
• Any result of the following infectious disease tests is positive: HIV; HCV; HBsAg; or HBcAb positive with HBV DNA copies positive; TPPA;
• Live vaccine ≤4 weeks prior to enrollment;
• For Ph+ ALL, TKI therapy ≤1 week prior to enrollment;
• History of anti-CD19 therapy or CAR-T or other gene-editing T cell therapy;
• Presence of ≥ grade 2 acute graft-versus-host disease (GVHD, Glucksberg criteria) or extensive chronic GVHD (Seattle criteria) that require treatment ≤4 weeks prior to enrollment, or during the study period the subject is required to receive anti-GCHD therapy in researcher's judgement;
• Presence of concomitant disease that require systemic steroids or other immune suppressive therapy during the study period in researcher's judgement; Allogeneic cell therapy (such as donor lymphocyte infusion, DLI) ≤4 weeks prior to enrollment;
• CNS stereotactic radiotherapy ≤4 weeks prior to enrollment;
• Toxicities related to previous therapy did not relieved to ≤1 grade, except hematological toxicity and alopecia;
• Known life-threatening hypersensitivity to cyclophosphamide or fludarabine, or presence of other intolerant conditions, or severe allergic constitution;
• Patients with active autoimmune disease (e.g., systemic lupus erythematosus, sjogren syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Hashimoto's thyroiditis, hypothyroidism which can be controlled by thyroid hormone replacement therapy is an exception);
• For patients that underwent or plan to undergo major surgical operation before CAR-T treatment, major surgery which required general anesthesia happened ≤4 weeks prior to enrollment, or did not be fully recovered and clinically stable prior to enrollment, or be anticipated to undergo major surgical operation which requires general anesthesia during the study;
• Took drug from other research≤28 days prior to enrollment;

Sponsors & Collaborators

• Peking University Third Hospital: lead
• Gracell Biotechnology Ltd.: collaborator

MeSH Terms

Conditions

Burkitt Lymphoma

Condition Hierarchy (Ancestors)

Epstein-Barr Virus Infections; Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections; Tumor Virus Infections; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Central Study Contacts

Hongmei Jing, Doctor

CONTACT

15611908428; hongmei_jing@163.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 14, 2020
• First Posted: October 20, 2020
• Study Start: March 15, 2021
• Primary Completion: December 15, 2023
• Study Completion (Estimated): December 15, 2035
• Last Updated: October 20, 2020

Record last verified: 2019-11